Biosimilars
Assay Focus

Biosimilars-Related Services

Helping You Take Advantage of the Potential in Biosimilars

Rely on the combined power of BioAgilytix’s veteran scientists, advanced platforms, and validated techniques to quickly progress the development of your promising biosimilars. Our scientists have experience supporting biosimilar studies with ligand binding assays, characterization, and stability testing on multiple platforms.

Find Answers to Your Biosimilars Questions:

Tell Us About Your Project

What are your specific assay needs? Let’s schedule a conversation to review your questions and requirements with one of our scientists.

Biosimilars Development: Demonstrating Biosimilarity

A biosimilar is a biological product that is highly similar to a reference biological product notwithstanding minor differences in clinically inactive components, and for which there are no clinically meaningful differences between the biological product and the reference product in terms of the safety, purity, and potency of the product. Biosimilars are not to be confused with generic chemical medicines, which use identical active ingredients. It is critical to demonstrate the comparability of a biosimilar to its originator product not only to ensure safety and efficacy but also to allow for drug substitution and exchangeability.

The Biosimilars Council reports that by 2020, brand biologic medicines worth an estimated $81 billion in global annual sales will lose their patents. This provides a significant opportunity for the development of lower cost biosimilar alternatives, and the biosimilars market is expected to expand more than 20-fold in the next 5 years.

 

biosimilars white paper

2013 Cai, Wake, Gouty paper

Analytical and bioanalytical assay challenges to support comparability studies for biosimilar drug development

For more information on why it is critical to establish analytical and bioanalytical equivalency between biosimilars and originators – and the unique challenges this presents.

Download White Paper

BioAgilytix Biosimilars-Related Services: Committed Expertise

The rise of biosimilars brings with it the promise of broader patient access to important medicines for serious diseases. BioAgilytix is committed to supporting this area of innovation by bringing together the best scientists, technologies, and processes needed to develop and deliver reliable, high-quality biosimilars for a wide range of disease states.

Our scientists have experience supporting biosimilar studies with ligand binding assays, characterization, and stability testing on multiple platforms. We also possess robust expertise in analyzing samples from rodents, humans, and non-human primates under non-GLP, GLP, and in performing analyses under GMP regulations.

biosimilars development

Optimal Platforms for Biosimilars Development: Sensitivity is Key

BioAgilytix is highly knowledgeable in the sensitivities of biologics development, and understands the challenges that biosimilar developers face. We have leading experience using the following platforms from our extensive technology suite to conduct immunogenicity and PK studies, biomarker studies, cell-based assays, ADA analyis, and NAb assays supporting biosimilars development.

elisa platform analytical device

ELISA

msd-ecl platform analytical device

MSD-ECL

gyrolab xl platform analytical device

Gyrolab xP

proteinsimple platform analytical device

ProteinSimple

biacore platform analytical device

Biacore

immunogenicity offer

bioanalytical buyers guide cell based assay services

The Bioanalytical Buyer's Guide: Choosing the Right CRO Partner

Download this helpful resource to discover the 8 key selection criteria you should consider when evaluating a bioanalytical CRO to ensure a successful partnership.

Download Now

Leverage BioAgilytix’s Expertise to Progress Your Biosimilars Development Efforts

The surge of upcoming patent expiries has driven demand for biosimilars – but without access to the originator’s molecular clone and cell bank, the exact fermentation and purification process, or the active drug substance, mimicking the performance of the branded original is extremely complex. Averaging over 15 years of bench experience, our veteran team of scientists has world-leading expertise in biosimilars development, and will apply that knowledge to optimally support your project. We are able to offer services under GLP, GMP, and GCP to meet your distinct regulatory requirements.

The rise of biosimilars brings with it the promise of broader patient access to important medicines for serious diseases. BioAgilytix is committed to supporting this area of innovation by bringing together the best scientists, technologies, and processes needed to develop and deliver reliable, high-quality biosimilars for a wide range of disease states.

biosimilars expertise

Our Biosimilars-Related Services Includes:

  • Immunogenicity
  • Pharmacokinetics (PK)
  • Biomarkers
  • Cell-Based Assays
  • ADA
  • NAb Assays

Speak to a Scientist

What would you like to discuss?

With whom will we be speaking?







Sign up for the quarterly newsletter?


pharmacokinetics icon

Pharmacokinetics (PK)

See how our PK expertise complements our immunogenicity services by evaluating absorption, distribution, metabolism and excretion characteristics of a product.

Explore our PK services

biomarkers icon

Biomarkers

Learn how we will translate our experience working with over 500 biomarkers in singleplex and multiplex formats to your project’s success.

See our biomarker expertise